A study on the utility of TAZ/PIPC in the treatment of nosocomial pneumonia - Comparison with MEPM
- Conditions
- osocomial pneumonia
- Registration Number
- JPRN-UMIN000003972
- Lead Sponsor
- Department of Infection Control and Prevention, Aichi Medical University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 160
Not provided
(1) Patients with a history of hypersensitivity to the ingredients of this product, such as shock (2) Children (younger than 16 years old) (3) Patients with infectious mononucleosis (4) Patients receiving sodium valproate (5) Pregnant women, lactating women, or patients possibly to be pregnant (6) Patients with hepatic, renal or cardiac diseases, immunodeficiency, other serious underlying diseases or complications, who have difficulty in evaluation of the efficacy of this product. (7) Patients in the group with severe disease (C group), for whom combination with antimicrobial agents is recommended in the guidelines for treatment of nosocomial pneumonia of the Japanese Respiratory Society (8) Other patients judged to be unsuitable as subjects by the physicians in charge
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method